ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
The Occurence of Inflammation and Oxidative Stress in Lung Diseases

This study has been completed.

Sponsors and Collaborators: Maastricht University Medical Center
ZonMw: The Netherlands Organisation for Health Research and Development
Information provided by: Maastricht University Medical Center
ClinicalTrials.gov Identifier: NCT00512967
  Purpose

Reactive oxygen species (ROS) are suggested to play a pivotal role in ILD. Little is known, however, about the endogenous antioxidant levels in ILD that can offer protection against ROS. It is expected that the high amount of ROS present in ILD will reduce the antioxidant levels. Therefore, antioxidant therapy to strengthen this reduced antioxidant defense might be efficacious in ILD treatment. Since ROS are capable of initiating and mediating inflammation, antioxidant therapy might also mitigate elevated inflammation. A candidate for antioxidant therapy is the flavonoid quercetin that is known for its anti-oxidative and anti-inflammatory capacities.

The aim of the present study is to determine the antioxidant and inflammatory status in ILD, i.e. sarcoidosis and idiopathic pulmonary fibrosis (IPF). Furthermore, to evaluate the possible anti-inflammatory effects of antioxidants, the effect of quercetin will be examined on the ex vivo LPS-induced cytokine production in ILD


Condition
Interstitial Lung Diseases
Sarcoidosis
Idiopathic Pulmonary Fibrosis
COPD

MedlinePlus related topics:   Antioxidants    Pulmonary Fibrosis    Sarcoidosis    Stress   

ChemIDplus related topics:   Quercetin   

U.S. FDA Resources

Study Type:   Observational
Study Design:   Case-Only, Cross-Sectional
Official Title:   The Inflammatory and Antioxidant Status in Pulmonary Sarcoidosis, Idiopathic Pulmonary Fibrosis and COPD: a Potential Role for Antioxidants

Further study details as provided by Maastricht University Medical Center:

Biospecimen Retention:   Samples With DNA

Biospecimen Description:

blood samples were collected


Enrollment:   76
Study Start Date:   September 2005
Study Completion Date:   June 2006

Groups/Cohorts
sarcoidosis
21 onset patients, non-treated
IPF
15 IPF patients, partially treated
COPD
15 COPD patients within 24 hours after their last exacerbation
controls
25 healthy controls, matched for age and gender

Show detailed description  Show Detailed Description

  Eligibility
Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample

Study Population

lung patients visiting the out-patient clinic of the Academic Hospital Maastricht


Criteria

Inclusion Criteria:

  • clinical diagnosis of pulmonary sarcoidosis, IPF or COPD
  • no treatment for sarcoidosis
  • last exacerbation not more than 24 hours ago for COPD
  • healthy controls
  • no smoking for sarcoidosis and IPF

Exclusion Criteria:

  • pregnancy
  • use of vitamins or food supplements
  • clinical diagnosis (and treatment) of other diseases
  • symptoms of sarcoidosis in other organs besides the lung
  Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00512967

Locations
Netherlands
Maastricht University    
      Maastricht, Netherlands, 6224 LH

Sponsors and Collaborators
Maastricht University Medical Center
ZonMw: The Netherlands Organisation for Health Research and Development

Investigators
Study Chair:     Aalt Bast, PhD     Maastricht University Medical Center    
Principal Investigator:     Agnes W Boots, PhD     Maastricht University Medical Center    
Study Director:     Guido R Haenen, PhD     Maastricht University Medical Center    
  More Information


Responsible Party:   Maastricht University ( Dr. A.W. Boots )
Study ID Numbers:   MEC 03-112
First Received:   July 19, 2007
Last Updated:   February 25, 2008
ClinicalTrials.gov Identifier:   NCT00512967
Health Authority:   Netherlands: Medical Ethics Review Committee (METC)

Keywords provided by Maastricht University Medical Center:
oxidative stress  
antioxidants  
inflammation  
quercetin  

Study placed in the following topic categories:
Lung Diseases, Interstitial
Fibrosis
Hamman-Rich syndrome
Stress
Sarcoidosis
Pulmonary Fibrosis
Inflammation
Lymphatic Diseases
Sarcoidosis, pulmonary
Respiratory Tract Diseases
Lung Diseases
Fibrosing alveolitis
Lymphoproliferative Disorders
Quercetin
Sarcoidosis, Pulmonary

Additional relevant MeSH terms:
Pathologic Processes

ClinicalTrials.gov processed this record on October 10, 2008




Links to all studies - primarily for crawlers